Pathogenic Variants in Cardiomyopathy Disorder Genes Underlie Pediatric Myocarditis—Further Impact of Heterozygous Immune Disorder Gene Variants?

Franziska Seidel 1,2,3,4,5, Kai Thorsten Laser 6, Karin Klingel 7, Josephine Dartsch 1,3, Simon Theisen 1,3,4, Thomas Pickardt 8, Manuel Holtgrewe 9,10, Anna Gärtner 11, Felix Berger 2,4,5, Dieter Beule 1,9, Hendrik Milting 11, Stephan Schubert 2,4,6, Sabine Klaassen 1,3,4,5,7 and Jirko Kühnisch 1,3,4,*

Abstract: Myocarditis is an inflammatory disease of the heart. Pediatric myocarditis with the dilated cardiomyopathy (DCM) phenotype may be caused by likely pathogenic or pathogenic genetic variants [(L)P] in cardiomyopathy (CMP) genes. Systematic analysis of immune disorder gene defects has not been performed so far. We analyzed 12 patients with biopsy-proven myocarditis and the DCM phenotype together with their parents using whole-exome sequencing (WES). The WES data were filtered for rare pathogenic variants in CMP (n = 89) and immune disorder genes (n = 631). Twelve children with a median age of 2.9 (1.0–6.8) years had a mean left ventricular ejection fraction of 28% (22–32%) and myocarditis was confirmed by endomyocardial biopsy. Patients with primary immunodeficiency were excluded from the study. Four patients underwent implantation of a ventricular assist device and subsequent heart transplantation. Genetic analysis of the 12 families revealed an (L)P variant in the CMP gene in 8/12 index patients explaining DCM. Screening of recessive immune disorder genes identified a heterozygous (L)P variant in 3/12 index patients. This study supports the genetic impact of CMP genes for pediatric myocarditis with the DCM phenotype. Piloting the idea that additional immune-related genetic defects promote myocarditis suggests that the presence of heterozygous variants in these genes needs further investigation. Altered cilium function might play an additional role in inducing inflammation in the context of CMP.

Keywords: dilated cardiomyopathy; myocarditis; genetic; immune; pathogenic variant
1. Introduction

Myocarditis is an inflammatory entity of the myocardium that may lead to severe heart failure [1]. In the pediatric setting, myocarditis is particularly common in children under two years of age and in adolescents [2,3]. Especially children under two years of age develop the phenotype of dilated cardiomyopathy (DCM) in more than 50% that present with severely impaired left ventricular cardiac function and left ventricular dilatation [4,5]. The clinical courses of these children are severe including increased mortality, the frequent need for mechanical circulatory support (MCS), or heart transplantation (HTx) [5–7]. Pediatric DCM, a primary form of cardiomyopathy (CMP) in children, has a peak incidence in the first years of life [8,9]. As there is little difference between the two entities in clinical presentation, differentiation on the basis of clinical data alone is often difficult and usually requires further diagnostic validation with an endomyocardial biopsy (EMB) [10,11]. Most frequently, pediatric myocarditis cases diagnosed with positive EMB are affected by healing/chronic myocarditis and substantial ventricular remodeling with the need for MCS in approximately 20% and HTx in 10% of cases [6,12].

Myocarditis arises mostly from infectious causes, less frequently from (auto)immunological predisposition, or drug toxicity [13]. Viral infection with parvovirus B19 (PVB19), enteroviruses, and human herpes virus 6 (HHV-6) are among the classic pathogens of myocarditis [14]. Mechanistically, myocarditis involves innate and adaptive immune system components that become activated after virus entry via their common receptors (e.g., coxsackie–adenoviral receptor (CAR), decay-accelerating factor (DAF)) and activation of the innate immune response via toll-like receptors (e.g., TLR3, TLR4). Consequently, natural killer cells and macrophages become recruited to the myocardium, their activation releases IFN-α/β, and initiates T-/B-lymphocyte proliferation and activation [1,15,16]. Subsequently, T-lymphocytes target viral proteins but also expose mimicry mechanisms towards myocardial proteins such as the myosin heavy chain [16,17]. This suggests that myocarditis is an intertwined pathology of immune defense against external pathogens and autoimmune response to myocardial antigens [1,16]. The frequent association of DCM with inflammation implicates a critical predisposition of the myocardium [12,18–20].

Recently, we showed that pediatric myocarditis with the DCM phenotype is due to pathogenic or likely pathogenic genetic variants [(L)P] in CMP disease genes [12]. In this study, we could discriminate between a clinical group presenting myocarditis with the DCM phenotype (MYC-DCM) and myocarditis without the DCM phenotype (MYC-nonDCM). Clinically, the MYC-DCM group had much worse outcomes compared to the MYC-nonDCM group. Most children of the MYC-nonDCM group recovered after myocarditis. However, patients of the MYC-DCM group often required MCS or HTx and carry more frequently genetic (L)P variants. This suggests that a proportion of pediatric patients with myocarditis have an underlying primary, genetically determined DCM.

The potential role of genetic factors in immune disorder genes was assessed in pediatric patients with acute myocarditis [21]. However, this study could not identify the enrichment of rare heterozygous, homozygous genetic variants in TLR3 and IFN-α/β associated genes. Homozygous variants in CMP disease genes such as desmoplakin (DSP) and troponin I3 (TNNI3) were identified in pediatric patients with myocarditis [21]. The critical role of genetic (L)P variants in DSP and TNNI3 was replicated in several studies involving children or adults with myocarditis [12,18,19,22–24]. Another recent study identified protein-truncating variants in titin (TTN-tv), filamin C (FLNC), and DSP, which are CMP disease-related genes, in a cohort of adult lymphocytic myocarditis cases [25]. A seminal study linked an immunoregulatory locus comprising the major histocompatibility complex, class II, DR beta 4 (HLA-DRB4) with idiopathic DCM [26]. Single-case or small cohort studies identified Interleukin 12 receptor subunit beta 1 (IL12RB1) variants and the TLR3 p.Pro554Ser variant as genetic susceptibility factors for myocarditis [27,28]. Altogether, this suggests that mutation of CMP genes is associated with myocarditis, and genetic defects of immune system components are heterogeneous. The impact of hetero-, hemi-, or homozygous genetic variants in a broader spectrum of known immune disease genes...
was not systematically explored in mono- or oligogenic traits so far. Here, we test the hypothesis that patients with severe DCM and biopsy-proven myocarditis carry genetic variants in CMP and immune disease genes utilizing a family-based genetic approach.

2. Material and Methods

2.1. Study Population

Clinical data from patients below 18 years of age with suspected myocarditis were extracted from medical records at the Pediatric Cardiology Departments of the Charité-Universitätsmedizin Berlin, the German Heart Center Berlin, and the Heart- and Diabetes-center NRW, Bad Oeynhausen, Germany between January 2010 and April 2021. Starting in 2013, six patients were also enrolled in MYKKE, a prospective multicenter registry for suspected myocarditis (clinical trial identifier: NCT02590341; accessed on 1 April 2021). The online database of the MYKKE registry includes patients’ clinical data and is hosted by the Competence Network for Congenital Heart Defects, Germany [4]. This study used a family approach including genetic analysis of the index patient and the respective parents.

The inclusion criteria of index patients were the following: Biopsy-proven myocarditis and present DCM phenotype at admission, as previously described before [12]. Patients with structural congenital heart defects, syndromic disorders, situs inversus, or metabolic, mitochondrial, or neuromuscular disease were excluded from the study. Clinical and diagnostic assessments including laboratory parameters and cardiac imaging were performed routinely. The follow-up for the occurrence of major adverse cardiac events such as malign arrhythmia, MCS, HTx, and/or all-cause death started with the date of admission. The study was conducted according to the guidelines of the Declaration of Helsinki, approved by the institutional ethics committee (Charité-Universitätsmedizin Berlin, ID EA2/083/13, EA2/131/10, EA2/074/13; University Clinic of Ruhr University Bochum, Bad Oeynhausen for MYKKE 65/2013 and Biobank 21/2013). All parents/guardians of patients <18 years gave written informed consent.

2.2. Statistical Analysis for Clinical Data

Categorical variables were summarized by frequencies and percentages. For continuous measures, data were presented as median values with the interquartile range (IQR). Pearson’s chi-square test and Fisher’s exact test were used to compare dichotomous variables. For the comparison of independent groups, the Mann–Whitney U and Kruskal–Wallis tests were applied. A probability value of <0.05 was considered statistically significant. Data were analyzed using IBM Corp. Released 2017, IBM SPSS Statistics for Windows, Version 25.0. (Armonk, NY, USA).

2.3. Analysis of Endomyocardial Biopsies

Endomyocardial biopsies (EMB) were taken according to the clinical routine from the left, right, or both ventricles as a diagnostic approach or transmural specimen during VAD implantation from all patients (n = 12). All biopsies were analyzed histopathologically and immunohistochemically as previously described and by quantitative polymerase chain reaction (qPCR) for myocardial detection of viral RNA/DNA by one specialized center for Cardiopathology (Institute for Pathology and Neuropathology, University Hospital Tübingen, Tübingen, Germany) [14,29,30]. Histological analysis followed the Dallas criteria as the gold standard for the evaluation of myocarditis and was completed by different immunohistochemical staining [30]. The diagnosis of myocarditis was confirmed according to the established criteria and categorized in accordance with the WHO definition [31,32].

2.4. Next-Generation Sequencing (NGS) and Variant Calling

For NGS analysis, DNA was isolated from peripheral blood (Macherey-Nagel, Germany) and quality checked with Qubit (Invitrogen, Carlsbad, CA, USA) and Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA.) [33]. Whole-exome sequencing (WES) occurred at Genewiz (Azenta Life Sciences, Leipzig, Germany). The genomic DNA was
quantified using the Qubit 4.0 Fluorometer and qualified using the Agilent 5300 Fragment Analyzer. Enrichment probes were designed against the region of interest and synthesized through Twist Comprehensive Exome kit Biosciences (South San Francisco, CA, USA). Library preparation was performed according to the manufacturer’s guidelines. Briefly, the genomic DNA was fragmented enzymatically according to the manufacturer’s instructions. Fragmented DNA was cleaned up and end-repaired, as well as adenylated at the 3’ends. Adapters were ligated to the DNA fragments, and adapter-ligated DNA fragments were enriched with limited-cycle PCR. Adapter-ligated DNA fragments were validated using the Agilent Fragment Analyzer (Agilent Technologies, Santa Clara, CA, USA), and quantified using the Qubit 2.0 Fluorometer. Adapter-ligated DNA fragments were hybridized with biotinylated baits. The hybrid DNAs were captured by streptavidin-coated binding beads. After extensive washing, the captured DNAs were amplified and indexed with Illumina indexing primers. Post-captured DNA libraries were validated using the 5300 Fragment Analyzer (Agilent, Santa Clara, CA, USA) and quantified using the Agilent 2.0 Fluorometer. Illumina reagents and kits for DNA library sequencing cluster generation and sequencing were used for enrichment DNA sequencing. Post-captured libraries have been multiplexed on a flow-cell and loaded on the Illumina NovaSeq 6000 instrument according to the manufacturer’s instructions (Illumina, San Diego, CA, USA). The samples were sequenced using a 2 × 150 paired-end (PE) configuration. Image analysis and base calling were conducted by NovaSeq Control Software on the NovaSeq instrument. Raw sequencing data (bcl files) generated from Illumina NovaSeq were converted into fastq files and de-multiplexed using Illumina’s bcl2fastq software.

Alignment of WES raw data sets and variant calling was performed using the GRCh37 (hs37d5.fa) reference genome [33]. Briefly, the demultiplexing of libraries occurred with bcl2fastq v2.17.1.14, the reads were aligned using BWA-MEM v0.7.15 (Wellcome Trust Sanger Institute, Cambridge, UK) to the reference GRCh37 (hs37d5.fa), separate read groups were assigned for all reads from one lane, and duplicates were masked using Samblaster v0.1.24 (Ira Hall Lab, University of Virginia, VA, USA). FastQC was used for standard quality control. The variants were then called using GATK UnifiedGenotyper v3.7 (Broad Institute, Cambridge, MA, USA). The called variants were evaluated with Varfish using a minor allele frequency (MAF) < 0.0001 and mutation specification [34]. We used the Genome Aggregation Database (gnomAD v2.) as a genetic reference database for allele frequencies in a control cohort (https://gnomad.broadinstitute.org/; accessed on 1 April 2021, Broad Institute, Cambridge, MA, USA) [35]. We evaluated 89 validated CMP disease genes [33,36] and 631 validated immune disease genes (https://blueprintgenetics.com; accessed on 1 April 2021, Blueprint Genetics, Espoo, FIN) [37–39].

2.4.1. Gene List of 89 CMP Disease Genes

Variants in the following genes were bioinformatically evaluated and classified: ABCC9, ACTA1, ACTC1, ACTN2, ALMS1, ANKRD1, BAG3, BRAF, CALR3, CAV3, CBL, COX15, CRYAB, CSRPR3, DES, DMD (XL), DNAJC19, DOLK, DSC2, DSG2, DSP, DTNA, EMD (XL), EYA4, FBNI, FHL1 (XL), FHL2, FKRP, FKTN, FXN, GAA, GATAD1, GLA (XL), HADHA, HCN4, HFE, HRAS, HSPB8, JPH2, JUP, KRAS, LAMA2, LAMA4, LAMP2 (XL), LDB3, LMNA, MAP2K1, MAP2K2, MIB1, MYBPC3, MYH6, MYH7, MYL2, MYL3, MYLK2, MYOZ2, MYBP1, NEXN, NKX2-5, NRAS, PDLIM3, PKP2, PLN, PRDM16, PKRAG2, PTPN11, RAF1, RBM20, RYR2, SCN5A, SCO2, SDHA, SGCB, SGC, SHOC2, SOS1, TAFAZZIN (XL), TBX20, TCAP, TGBF3, TMEM43, TNNC1, TNNI3, TNNT2, TPM1, TTN, TTR, VCL. Genes given in regular format were considered disease-causing only with autosomal dominant (AD) inheritance. Genes in bold were considered disease-causing only with autosomal recessive (AR) inheritance.

2.4.2. Gene List of 631 Immune Disease Genes

Variants in the following genes were bioinformatically evaluated and classified: ABCB7 (XL), ABCG5, ABCG8, ACD, ACP5, ACT1, ACTN1, ADA, ADAM17, ADAMS13,
ADAMTS3, ADAR, ADIPOQ, ADIPOR2, AICDA, AIRE, AK2, ALAS2 (XL), ALPI, ANKRD11, ANKRD26, AP1S3, AP3B1, AP3D1, APOLI, ARHGEF1, ARM4, ARPC1B, ATM, ATR, ATRX (XL), B2M, BACH2, BCL10, BCL11B, BCO1, BLM, BLNK, BLOC1S5, BLOC1S6, BRAF, BRCA1, BRCA2, BRIP1, BTK (XL), C1QA, C1QB, C1QBP, C1QC, CIR, C1S, C2, C3, C3AR1, C4BPAl, C4BPB, C5, C5AR1, C5AR2, C6, C7, C8A, C8B, C8G, C9, CARD11, CARD14, CARD9, CASP10, CASP8, CBL, CBEB1, CDDC103, CDDC14, CDDC39, CDDC40, CDDC65, CCNK, CCNO, CD19, CD247, CD27, CD3D, CD3E, CD3G, CD40, CD40LG (XL), CD46, CD55, CD59, CD70, CD79A, CD79B, CD8A, CD93, CD91, CDC42, CDA7A, CDK9, CDKN2A, CEBPA, CEBPE, CENPF, CFB, CFD, CHFHR5, CIF, CIP (XL), CFTF, CHD7, CHEK2, CIB1, CITA, CLCN7, CLC7A, CLP8, CLU, COG6, COL11A1, COPA, CORO1A, CPT2, CR2, CREBBP, CRP, CSF2RA (XL), CSF2RB, CSF3R, CTC1, CTLA4, CTNNB1, CTPS1, CTSC, CXCRL2, CXXCR4, CYBA, CYBB (XL), CYCS, CYP27A1, DBR1, DCLRE1B, DCLRE1C, DDX11, DDX41, DDX58, DEF6, DGAT1, DGKE, DHFR, DKCI (XL), DNAAF1, DNAAF2, DNAAF5, DNAH11, DNAH12, DNAH12, DNAJ2C1, DNA1, DNAE1L, DNAE2, DNMT3B, DOC2, DOCK1, DR1, DRTNBP1, EFL1, EIF2AK3, ELAN, EP300, EPcam, EP53, EPO, ERCC2, ERCC3, ERCC4, ERCC6, ETV6, EXT1, FAAIP10, FAAIP24, FADD, FANCA, FANC2, FANC, FANC, FANC, FANC, FANC, FANC, FANC, FANC, FAS, FASLG, FAT4, FCGR3A, FCHO1, FCN1, FCN2, FCN3, FERMT1, FERMT3, FLG, FLJ11, FLNA, FOXN1, FOXP3 (XR), FPR1, G6PC3, G6PD (XL), GAS2L2, GAS8, GATA1 (XL), GATA2, GBA, GFI1, GFI1B, GINS1, GLRX5, GNE, GP1BA, GP1BB, GP9, GTF2H5, GUCY2C, HAVCR2, HAX1, HELLS, HMOX1, HNRNPK, HOXA11, HPS1, HPS3, HPS4, HPS5, HPS6, Hras, HSPA9, HYDIN, HYOU1, ICOS, ICOGL, IFI1H1, IFNAR1, IFNAR2, IFNGR1, IFNGR2, IGL1, IKBKB, IKZF1, IL10, IL1RA, IL1RB, IL12B1, IL12B2, IL12RB1, IL12RB2, IL17F, IL17RA, IL17RC, IL18BP, IL1RN, IL21, IL2RA, IL2RB, IL2RG (XL), IL36RN, IL6R, IL6ST, IL7R, INOS, INVS, IRAK3, IRAK4, IRAF2BP2, IRAF3, IRF3, IRF7, IRF8, IRF9, ISG15, ITCH, ITGA2, ITGA2B, ITGB2, ITGB3, ITPK1, JAK1, JAK2, JAK3, KDM1A, KDM6A (XL), KIF23, KLF1, KMT2A, KMT2D, KRAS, LAMTOR2, LAT, LCK, LCT, LIG1, LIG4, LP1A, LP2, LRBA, LRRCD8A, LYST, LZTR1, MAD2L2, MAGT1 (XL), MALTI1, MAN2B1, MANBA, MAPK2, MAPK2, MAPK4, MAPK8, MAPS1, MAP2, MSTL, MAT2A, MBL2, MCMAS, MCM4, MECOM, MEFV, MLH1, MLL1, MOGS, MPL, MPQ, MRAS, MS4A1, MS4B2, MS6H, MSN (XL), MTHFD1, MVK, MYD88, MYH9, MYO5A, MYO5B, MYS51, NAF1, NBS1, NBEAL2, NBN, NCF1, NCF2, NCF4, NCKAP1L1, NCSN, NEUROG3, NF1, NFAT5, NFE2L2, NFIL3, NFKB1, NFKB2, NFKBIA, NEKJ1, NHP2, NLRPC4, NRIP2, NLRP12, NLRP3, NME8, NOD2, NOP10, NRAS, NSMCE2, NSMCE3, NUP214, OA51, ODF1 (XL), ORAI1, OSTM1, OTUD6B, OTULIN, PALB2, PARN, PAX5, PEPD, PGMS, PIGA (XL), PIHID3 (XL), PIK3CD, PIK3R1, PLCG2, PLEKHM1, PLG, PMM2, PNS2, PNP, POLA1 (XL), POLD1, POLD2, POLE, POLR3A, POLR3C, POLR3E, POMP, POT1, PPP1CB, PRF1, PRG4, PRKACG, PRKCD, PRKDC, PSEN1, PSENEN, PSMB8, PSMG2, PSTPIP1, PTK7, PTPN11, PTPRC, PTX3, PUS1, RAB27A, RAC2, RAD50, RAD51C, RAF1, RAG1, RAG2, RANBP2, RAP1A, RAP1B, RASA2, RASGRPL1, RBCK1, RBMSA, RECQL4, REL, RELA, REB, RFWD3, RF5, RFX, RFXANK, RHOIH, RIPK1, RIT1, RMRP, RNASEH2A, RNASEH2B, RNASEH2C, RNFI68, RNF31, RNU4ATAC, ROCR, RPRG (XL), RPL10 (XL), RPL11, RPL15, RPL18, RPL19, RPL26, RPL27, RPL31, RPL35A, RPL36, RPL5, RPL9, RPS10, RPS14, RPS15, RPS15A, RPS19, RPS24, RPS26, RPS27A, RPS28, RPS29, RPS5, RRS4, RSRHI, RSPH3, RSPH4, RSRHI, RETL1, RUNX1, SAMD9, SAMD9L1, SAMD11, SAR1B, SBDS, SBFI2, SEC36B, SEC61A1, SEMA5E, SERPING1, SH2D1A (XL), SHB3P2, SH3KBP1 (XL), SHOC2, SIG12L, SLCO1A2, SLCA192, SLC25A8, SLC26A3, SLC29A3, SLC35A1, SLC35C1, SLC37A4, SLC39A4, SLC39A7, SLC46A1, SLC5A1, SLC7A7, SLC9A3, SLFN14, SLX4, SMARCA1, SMARCDB2, SNX10, SOS1, SOS2, SP100, SPAGL, SPINK5, SPINT2, SPPL2A, SPRED1, SRC, SRRP54, SRP72, STAT1, STAT2A, STAT3, STAT5B, STIM1, STK36, STK4, STX11, STX3, STXB2P1, STXB3P3, TAPI, TAP2, TAPBP, TASP1, TATAF (XL), TBK1, TBX1, TCF3, TCIRG1, TCN2, TERC, TERF2, TERF2IP, TERT, TGFB1, TGFB1, TGFB2, THBD, THPO, THRA, THRB, TICAM1, TIN2, TIRAP, TL1R3, TMC6, TMC7, TMEM173, TNEAIP3, TNFRSF1A, TNFRSF1B, TNFRSF1C, TNFRSF1A, TNFRSF4, TNFRSF9, TNFRSF11, TNFRSF12, TOP2B, TP53,
TPP2, TRAC, TRADD, TRAF3, TRAF3IP2, TREX1, TRIM22, TRNT1, TSR2 (XL), TTC37, TTC7A, TUBB1, TYK2, UBE2T, UNCI19, UNCI3D, UNC93B1, UNG, USB1, USP18, VPS13B, VPS45, VSG4 (XL), VTN, WAS (XL), WDR1, WIPF1, WRAP53, XIAP (XL), XRC2, ZAP70, ZBTB24, ZCCHC8, ZMYND10, ZNF341. Genes given in regular format were considered disease-causing only with AD inheritance. Genes in **bold** were considered disease-causing only with AR inheritance. Genes in underlined **bold** were considered disease-causing with AD or AR inheritance. Genes with X-linked (XL) inheritance are indicated.

2.5. Genetic Analysis and Variant Classification

All filtered genetic variants were classified as pathogenic (P), likely pathogenic (LP), or a variant of uncertain significance (VUS) according to the guidelines of the American College of Medical Genetics and Genomics (ACMG) [40,41]. The MAF for variant filtering was <0.0001. Novel (L)P genetic variants will be deposited in the National Center for Biotechnology (NCBI) database ClinVar, available at: [https://www.ncbi.nlm.nih.gov/clinvar/submitters/506935/](https://www.ncbi.nlm.nih.gov/clinvar/submitters/506935/) (accessed on 1 April 2021, NCBI, Bethesda, MD, USA). The filter criteria for the 89 CMP disease genes included the following variants: Missense, protein length changing, splice effects (until +4 donor, until -4 acceptor site) in either genetic status (hetero-, homo-, hemizygous). The filter criteria for the 631 immune disease genes included the following variants: Missense only when annotated in ClinVar as (L)P variant or appear homo-/hemizygous, protein length changing, splice effects (until +4 donor, until -4 acceptor site) in either genetic status (hetero-, homo-, hemizygous). The following variant types were assessed: Single nucleotide variants (SNV), insertion/deletion (indel), and multi-nucleotide variants (MNV). Variant annotation occurred according to Ensembl ([http://www.ensembl.org/index.html](http://www.ensembl.org/index.html); accessed on 1 April 2021, European Bioinformatics Institute (EMBL-EBI), Hinxton Cambridge, UK).

Variant classification was performed according to ACMG guidelines [41]. The term PV51 was applied when loss of function (LOF), truncating variants are a proven CMP disease mechanism. PV51 was applied for DSP, BAG3, and TNNI3 only. For TTN-tv, we did not apply PV51. The ACMG terms PM5 or PS1 were activated when published LP/P variants occurred at the same amino acid position or amino acid exchange, respectively. PS3 was applied when database evidence, e.g., PubMed ([https://pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov); accessed on 1 April 2021, NCBI, Bethesda, MD, USA), Ensembl ([http://www.ensembl.org/index.html](http://www.ensembl.org/index.html), accessed on 1 April 2021), UniProt ([https://www.uniprot.org/](https://www.uniprot.org/); accessed on 1 April 2021, EMBL-EBI, Hinxton Cambridge, UK), or ClinVar ([https://www.ncbi.nlm.nih.gov/clinvar/](https://www.ncbi.nlm.nih.gov/clinvar/); accessed on 1 April 2021, NCBI, Bethesda, MD, USA), provided a clear pathological impact of the variant. PM1 was used when variants in proximity affected the functional domain or LP/P variants accumulated close to the analyzed variant. The ACMG term PM2 was activated at a gnomAD MAF < 0.0001. PM4 was applied for protein-length-changing variants due to coding sequence changes. PM6 was activated when a de novo variant was detected without confirmation of paternity and maternity. PP3 was activated when in silico prediction tools, e.g., MT2 ([http://www.mutationtaster.org/](http://www.mutationtaster.org/); accessed on 1 April 2021, Bioinformatics and Translational Genetics, Berlin Institute of Health (BIH), Berlin, Germany) or Provean ([http://provean.jcvi.org/index.php](http://provean.jcvi.org/index.php); accessed on 1 April 2021, J. Craig Venter Institute, La Jolla, CA, USA), provided a negative impact of the variant. For classification, the National Center for Biotechnology (NCBI) database ClinVar ([https://www.ncbi.nlm.nih.gov/clinvar/](https://www.ncbi.nlm.nih.gov/clinvar/); accessed on 1 April 2021, NCBI, Bethesda, MD, USA) was applied. Missense variants in TTN were not evaluated. The impact of TTN length-changing variants was validated according to the splice pattern displayed at cardiodb ([https://www.cardiodb.org/titin](https://www.cardiodb.org/titin); accessed on 1 April 2021, Medical Research Council (MRC), Imperial College London, London, UK) [42]. Genetic variants detected in index patients were traced in first-degree family members to determine de novo mutation or segregation. The Combined Annotation-Dependent Depletion (CADD) score was calculated for all variants ([https://cadd.gs.washington.edu/score](https://cadd.gs.washington.edu/score); accessed on 1 April 2021, BIH, Berlin, Germany) [43]. The CADD score is a quantitative prioritization approach for genetic
variants implementing multiple computational predictions including conservation metrics, functional genomic information, transcript information, and protein scores. The CADD score ranges from 1 to 99, and higher values indicate a more deleterious impact of a genetic alteration. The threshold > 10–20 indicates deleterious substitutions.

3. Results

3.1. Clinical Characterization

We enrolled 12 families including the pediatric index patient \( (n = 12) \) and both parents \( (n = 24) \). The index patients had a median age of 1.6 (0.8–8.0) years, including five males and seven females (Table 1). All children presented with a DCM phenotype. The mean left ventricular ejection fraction (LVEF) was 23% (21–30%) and the Z-Score of the left ventricular internal dimension at end-diastole (LVIDd) 6.6 (5.4–8.0). All had heart failure symptoms, received heart failure medication, and needed inotropic support. As immunological events, in seven patients, a viral respiratory infection within six weeks before admission was determined. One patient received vaccination against tetanus, diphtheria, whooping cough, haemophilus influenza b, polio, and hepatitis B one week before admission. Another patient was a small-gestational-age premature infant (index Family #5) and one was diagnosed later in life with Morbus Crohn (index Family #9). Severe, underlying immune disorders were excluded in all patients and parents during in-depth clinical assessment. EMB diagnosis revealed myocarditis-associated inflammation in all patients: Acute myocarditis \( n = 1 \), chronic/healing myocarditis \( n = 8 \), and unspecific macrophage dominated inflammation \( n = 3 \). Myocardial virus was detected in 6 out of 12 patients (PVB19, \( n = 2 \); HHV-6, \( n = 4 \)). Most of these patients had low viral loads \( (n = 5) \). Eleven patients underwent implantation of a ventricular assist device (VAD) and nine patients subsequently received HTx; none died. One patient could be weaned from VAD. This patient had moderate viral myocardial PVB19 levels.

3.2. Identification of Genetic CMP Disease Variants

Genetic analysis of the 12 families revealed an (L)P variant in a CMP gene in 8/12 index patients related to DCM (Figure 1, Table 2). Assessing genetic variants in 89 CMP disease genes yielded one (L)P variant in eight patients, at least one VUS in three patients, and no genetic CMP variant was found in one patient. In the index patient of family #10, the compound heterozygous genotype of two VUS missense variants in fukutin (FKTN), inherited in trans from the mother and father, likely explains the clinical phenotype composed of skeletal myopathy and DCM [44]. From these eight (L)P variants, six were missense and two emerged as stop gain variants. For instance, the truncating variant TTN p.Y8199* is annotated as (L)P variant (VCV000223326). All these (L)P variants have a CADD value > 23. Three (L)P variants appeared de novo, and one was homozygous (Figure 2). Four (L)P variants were novel and have not been reported in ClinVar so far. These genetic variants were found in troponin C1, slow skeletal and cardiac type (TNNC1) p.G34S (de novo, index patient of family #2), TNNI3 p.E182Q (de novo, index patient of family #7), TNNI3 p.L49Q (hom, family #3), and TTN p.Y8199 * (stop gain, family #9). The high yield of CMP causative (L)P variants reflects the severe clinical stage of the analyzed pediatric cohort.
## Table 1. Patient characteristics.

| Category                                      | Description                                  | n = 12 |
|-----------------------------------------------|----------------------------------------------|--------|
| **General information**                       |                                              |        |
| Male                                          | 5 (42)                                       |        |
| Age (years)                                   | 1.6 (0.8–8.0)                               |        |
| BSA (m²)                                      | 0.5 (0.3–0.9)                               |        |
| **Symptoms**                                  |                                              |        |
| NYHA                                          |                                              |        |
| I                                             | 0 (0)                                        |        |
| II                                            | 1 (8)                                        |        |
| III                                           | 1 (8)                                        |        |
| IV                                            | 10 (84)                                      |        |
| Angina pectoris                               | 1 (8)                                        |        |
| Decompensation                                | 12 (100)                                     |        |
| Gastrointestinal symptoms                     |                                              |        |
| Infection (<6 weeks)                          | 7 (58)                                       |        |
| Fever (<6 weeks)                              | 3 (25)                                       |        |
| **ECG**                                       |                                              |        |
| ST-elevation                                  | 0 (0)                                        |        |
| T-inversion                                   | 8 (67)                                       |        |
| Arrhythmias *                                 | 5 (42)                                       |        |
| **Laboratory**                                |                                              |        |
| NT-proBNP (pg/mL) (N = 8)                     | 23.025 (10.447–39.612)                      |        |
| Troponin elevated (N = 9)                     | 6 (67)                                       |        |
| **Echocardiography**                          |                                              |        |
| Z-score LVIDd                                 | 6.6 (5.4–8.0)                               |        |
| LVEF (%)                                      | 23 (21–30)                                   |        |
| **Endomyocardial Biopsy**                     |                                              |        |
| Myocardial virus detection                    | 6 (50)                                       |        |
| *Diagnosis EMB*                               |                                              |        |
| Acute myocarditis                             | 1 (8)                                        |        |
| Chronic healing myocarditis                   | 8 (67)                                       |        |
| Unspecific macrophages dominated inflammation | 1 (8)                                        |        |
| Unspecific macrophages dominated inflammation & DCM | 2 (17)                                      |        |
| **Medical treatment**                         |                                              |        |
| Heart failure medication                      | 13 (100)                                     |        |
| Inotropic medication                          | 13 (100)                                     |        |
| Immunoglobulin                                | 5 (42)                                       |        |
| Valganciclovir/Ganciclovir                    | 1 (8)                                        |        |
| Azathioprine/Prednisolone                     | 0 (0)                                        |        |
| **Devices**                                   |                                              |        |
| ICD                                           | 1 (8)                                        |        |
| Pacemaker                                     | 0 (0)                                        |        |
| VAD                                           | 10 (83)                                      |        |
| ECMO                                          | 0 (0)                                        |        |
| Weaned overall (N = 11)                       | 1 (8)                                        |        |
| **Complications**                             |                                              |        |
| Resuscitation                                 | 3 (25)                                       |        |
| HTx                                           | 8 (67)                                       |        |
| Death                                         | 0 (0)                                        |        |

Values are given as n (%) or median (interquartile range). * Arrhythmias were recorded with ECG and/or Holter-ECG and contained SVT, nsVT, VT. BSA = body surface area; DCM = dilated cardiomyopathy; ECG = Electrocardiogram; ECMO = extracorporal membrane oxygenation; EMB = endomyocardial biopsy; HTx = heart transplantation; ICD = implantable cardioverter-defibrillator; LVEF = left ventricular ejection fraction; LVIDd = left ventricular internal dimension at end-diastole; nsVT = non-sustained ventricular tachycardia; NT-proBNP = N-terminal pro brain natriuretic peptide; NYHA = New York Heart Association; SVT = supraventricular tachycardia; VAD = ventricular assist device; VT = ventricular tachycardia.
Genetic analysis of the 12 families revealed an (L)P variant in an immune disorder gene in 3/12 index patients. More specifically, genetic analysis of 631 immune disease genes yielded at least a VUS in nine patients and no genetic immune variant in three patients (Table 2). Overall, 15 variants were detected, including 3 (L)P variants and 12 VUS. These comprise six stop gain (truncation) variants, five splice region variants, two missense variants, and one in-frame deletion variant. All three (L)P variants were annotated in ClinVar as (L)P, are in a heterozygous state, have CADD values >30, and represent stop gain variants: Dynein axonemal heavy chain 11 (DNAH11) p.R2051*, FA complementation group C (FANCC) p.R548*, and sperm-associated antigen 1 (SPAG1) p.Q672* (Figure 2). Of note, these variants were associated with recessive inheritance for Fanconi anemia, complementation group C (FANCC), primary ciliary dyskinesia 7 (DNAH11), and primary ciliary dyskinesis 28 (SPAG1) so far. Within the 12 families, three variants were found in FANCC and FA complementation group M (FANCM) that were associated with Fanconi anemia and spermatogenic failure, respectively. Considering the molecular function of the immune disease genes, we observe an accumulation of variants in genes directly or indirectly associated with ciliary transport: Coiled-coil domain containing 40 (CCDC40), dynein axonemal heavy chain 9 (DNAH9), DNAH11, PIH1 domain-containing protein 3 (PIH1D3), and SPAG1. Further analysis excluded another missense variant in trans of the same gene for all filtered 15 immune gene variants. This dismisses compound heterozygosity for these genes. The CMP variant TTN p.Y8199* was maternally inherited in the index patient of family #1, while both immune-related variants originate from the father (Figure 2). Whether such an allelic combination is relevant for the development of myocarditis with the DCM phenotype should be tested in larger cohorts.

Figure 1. Study flow chart of the genetic evaluation after whole-exome sequencing (WES), including only patients with biopsy-proven myocarditis and phenotype of dilated cardiomyopathy (DCM). Cardiomyopathy (CMP) disease genes and immune disease genes were filtered with minor allele frequency (MAF) of $10^{-4}$ for pathogenic and likely pathogenic, (L)P, variants. Filtering for cardiomyopathy and immune disease genes included all heterozygous (het), homozygous (hom), and hemizygous (hemi) variants. Analysis of cardiomyopathy disease genes included all missense, protein length changing, and splice effect variants. Analysis of immune disease genes included all protein length changing and splice effect variants, but only missense (L)P variants previously annotated in ClinVar.
Table 2. Genetic CMP and immune disease variants.

| Patient | Gene | Gene Class | Transcript | cDNA Position | Protein Position | Geno-Type | Consequence | ClinVar Annotation | Frequency GnomAD (Exomes) | CADD Value | ACMG Evaluation |
|---------|------|------------|------------|---------------|-----------------|-----------|-------------|-------------------|--------------------------|-------------|-----------------|
| Family #1 | TTN | CMP | ENSG00000155657 | c.66547C > T | p.R22183* | het | stop gain | VC_000223226 (2LP, 4P) | 0.0000040 | 67.0 | LP |
| | IRF7 | IMMUNE | ENSG00000185507 | c.21G > A | p.= | het | splice region | no | 0 | 5.8 | VUS |
| | CCDC40 | IMMUNE | ENSG00000141519 | c.31,32insAA GCCGGGCGCGGT | p.S11* | het | stop gain | no | 0.000308 | 21.9 | VUS |
| Family #2 | TNNC1 | CMP | ENSG00000114854 | c.100G > A | p.G34S | het | de novo, missense | no | 0 | 25.6 | LP |
| | FBN1 | CMP | ENSG00000166147 | c.6416A > G | p.H2139R | het | missense | VC000238082 (4VUS) | no | 0.000008 | 23.1 | VUS |
| | DMD | XLD,XLR | ENSG00000198947 | c.767A > G | p.Q256R | hemi | missense | VCV00000000006 | no | 0.000066 | 23.6 | VUS |
| | DNAH11 | IMMUNE | ENSG00000105877 | c.6151C > T | p.R2051* | het | stop gain | VCV00000114854 (1P) | 0.00017 | 40.0 | LP (het) |
| Family #3 | TNNJ3 | CMP | ENSG00000129991 | c.1461T > A | p.L49Q | hom | missense | no | 0 | 29.2 | LP |
| | SPCG1 | IMMUNE | ENSG00000104450 | c.2014C > T | p.Q672* | het | stop gain | VCV0000088683 (1LP, 5P) | 0.000082 | 38.0 | LP (het) |
| | FANCM | IMMUNE | ENSG00000187790 | c.4223-4A > G | p.? | het | splice region | VCV0001104556 (1LV, 1LB) | 0.000058 | 8.3 | VUS |
| Family #4 | MYH7 | CMP | ENSG00000092054 | c.644C > T | p.T215I | het | de novo, missense | VC0000037697 (1LV, 1LB) | 0 | 24.8 | LP |
| Family #5 | MYLK2 | CMP | ENSG00000101306 | c.266G > T | p.G89V | het | missense | no | 0 | 23.4 | VUS |
| | SGCG | CMP | ENSG00000102683 | c.631A > G | p.I211V | het | missense | no | 0 | 0.17 | VUS |
| Family #6 | DNAH9 | IMMUNE | ENSG00000007174 | c.10479C > T | p.= | het | splice region | no | 0.000079 | 6.5 | VUS |
| Family #7 | TNNJ3 | CMP | ENSG00000129991 | c.544G > C | p.E182Q | het | de novo, missense | no | 0 | 23.9 | LP |
| Family #8 | MYH7 | CMP | ENSG00000092054 | c.1633G > A | p.D545N | het | missense | VC0000026407 (2VUS, 1LP, 3P) | 0 | 26.1 | LP |
| | ATRX | XLD,XLR | ENSG00000085224 | c.6871A > G | p.I2291V | hemi | missense | VC000010899 (1LR, 3LB, 1VUS) | 0 | 16.4 | VUS |
| | P1H13 | XLR | ENSG00000080572 | c.333G > A | p.= | hemi | splice region | no | 0 | 6.9 | VUS |
| Family #9 | TTN | CMP | ENSG00000155657 | c.24597C > A | p.Y8199* | het | stop gain | VCV00000970500 (2VUS) | 0 | 19.2 | VUS |
Table 2. Cont.

| Patient | Gene | Gene Class | Transcript | cDNA Position | Protein Position | Geno-Type | Consequence | ClinVar Annotation | CADD Value | GnomAD (Exomes) | ACMG Evaluation |
|---------|------|------------|------------|---------------|------------------|-----------|-------------|-------------------|------------|-----------------|-----------------|
| Family #10 [44] | FKTN | AR | CMP | ENSG00000106692 | c.895A > C | p.S299R | het | missense | VCV000254590 (2VUS) | 0.000008 | 29.1 | VUS |
| FKTN | AR | CMP | ENSG00000106692 | c.1325A > G | p.N442S | het | missense | VCV001022112 (1VUS) | 0.000004 | 25.2 | VUS |
| FANCC | AR | IMMUNE | ENSG00000158169 | c.1642C > T | p.R548* | het | stop gain | VCV000012047 (1LP, 15P) | 0.000025 | 36.0 | LP (het) |
| FLNA | XLR, XLD | IMMUNE | ENSG00000196924 | c.49C > G | p.P17A | hemi | missense | VCV000393067 (1US) | 0.000014 | 15.9 | VUS |
| RAC2 | IMMUNE | ENSG00000122040 | c.7 + 1del | p.=- | het | splice region | no | 0 | 31 | VUS |
| Family #11 | RYR2 | AD | CMP | ENSG00000198626 | c.3265G > A | p.E1089K | het | missense | VCV000180493 (1VUS, 1LP) | 0.000008 | 27.2 | LP |
| PLG | AD, AR | IMMUNE | ENSG00000122194 | c.1675C > T | p.Q559* | het | stop gain | VCV000220782 (2VUS) | 0.000019 | 21.9 | VUS |
| Family #12 | SDHA | AD, AR | CMP | ENSG00000073578 | c.1951G > A | p.E651K | het | missense | VCV000180493 (1VUS, 1LP) | 0.000008 | 27.2 | LP |
| DSC2 | AD, AR | CMP | ENSG00000134755 | c.1309G > C | p.V437L | het | missense | VCV000925401 (1VUS) | 0 | 22.8 | VUS |
| RBCK1 | AR | IMMUNE | ENSG00000125826 | c.383_384dup | p.A196Efs*39 | het | stop gain | no | 0 | 32.0 | VUS |

Abbreviations: ATRX—ATRX chromatin remodeler (XLD, XLR); CCDC40—coiled-coil domain containing 40 (AR); DMD—dystrophin (XL, XLR); DNAH9—dynein axonemal heavy chain 9 (AR); DNAH11—dynein axonemal heavy chain 11 (AR); DSC2—desmocollin 2 (AD, AR); FANC—FA complementation group C (AR); FANCM—FA complementation group M (AR); FBN1—fibrillin 1 (AD); FKTN—fukutin (AR); FLNA—filamin A (XLD, XLR); IRF7—interferon regulatory factor 7 (AR); MYH7—myosin heavy chain 7 (AD); MYLK2—myosin light chain kinase 2 (AD); PLG—plasminogen (AD, AR); PIH1D3—PIH1 domain-containing protein 3 (XLR; novel gene name DNAAF6); RAC2—Rac family small GTPase 2 (AD, AR); RBCK1—RANBP2-Type And CCHC4-Type Zinc Finger Containing 1 (AR); RYR2—ryanodine receptor 2 (AD, AR); SDHA—succinate dehydrogenase complex flavoprotein subunit A (AD, AR); SGCG—sarcoglycan gamma (AR); SPAG1—sperm associated antigen 1 (AR); TNNC1—troponin C1, slow skeletal and cardiac type (AD); TNNI3—troponin I3, cardiac type (AD); TTN—titin (AD); AD—autosomal dominant; AR—autosomal recessive; het—heterozygous; hom—homozygous; LP—likely pathogenic; P—pathogenic; VUS—variant of unknown significance; XLD—X-linked dominant; XLR—X-linked recessive; CADD—Combined Annotation-Dependent Depletion score.
Figure 2. Clinical and genetic evaluation of three selected families with CMP and myocarditis. 

(A) Pedigree of family #1 with the index patient 1-II:4 carrying a heterozygous titin truncating variant (TTN-tv), a splice variant in interferon regulatory factor 7 (IRF7), and a protein-truncating variant in coiled-coil domain containing 40 (CCDC40). The IRF7 and CCDC40 alleles are inherited from the father, while the TTN-tv allele is of maternal origin. 

(B') Echocardiographic images of 4-chamber view and (B") midventricular and short axis of individual 1-II:4 reveal severe left ventricular dilatation. 

(C) Pedigree of family #2 with the index patient 2-II:1 carrying a heterozygous de novo variant in troponin C1, slow skeletal and cardiac type (TNNC1), missense variants in fibrillin 1 (FBN1), as well as dystrophin (DMD), and a stop gain variant in dynein axonemal heavy chain 11 (DNAH11). All alleles are inherited from the mother. The DMD missense allele appears hemizygously. 

(D) Pedigree of family #3 with the index patient 3-II:2 exposes a homozygous missense variant in troponin I3, cardiac type (TNNI3), a stop gain variant in sperm-associated antigen 1 (SPAG1), and a splice variant in FA complementation group M (FANCM). The SPAG1 allele is inherited from the mother. The parents are consanguine.
4. Discussion

Using a family-based approach, this study provides further evidence that pediatric myocarditis with the DCM phenotype can be genetically caused by the mutation of established CMP disease genes. The spectrum of (L)P variants found in this study comprises missense variants in MYH7, TNNC1, TNNI3, ryanodine receptor 2 (RYR2) but also TTN-ťv, which is expected in a DCM cohort [36,45]. Thus, (L)P variants in CMP disease genes may underlie pediatric myocarditis, likely by affecting the tissue and cellular integrity of the myocardium. This study yielded an (L)P variant in a CMP gene in 8/12 patients reflecting the severe clinical disease course of the patients in the majority requiring VAD and HTx. All children with (L)P CMP variants presented with symptoms of severe heart failure, which is known to trigger further inflammation [46]. The elevated troponin levels indicate myocardial damage and might also trigger ongoing immune-induced damage to cardiomyocytes.

We piloted the idea that additional immune-related genetic defects promote inflammation. Heterozygous truncation variants with high CADD scores in immune-related genes were detected in 6/12 index patients and may have led to partial immunological dysfunction. Of note, this study did not identify genetic alterations in a single gene or isolated functional complex, indicating that myocarditis may be associated with several immune pathway defects. Three variants in immune genes were categorized in ClinVar as (L)P in association with the AR inheritance mode for Fanconi anemia, complementation group C (FANCC), primary ciliary dyskinesia 7 (DNAH11), and primary ciliary dyskinesia 28 (SPAG1). Due to limitations of the ACMG guidelines and ClinVar annotations, these (L)P variants in recessive genes cannot be classified as pathogenic in the heterozygous state. Importantly, these patients had no obvious signs of Fanconi anemia or primary ciliary dyskinesia. Interpretation of these variants is hampered by a lack of knowledge about mild clinical signs in the heterozygous genotype. The heterozygous variant FANCC, c.1642C > T, p.R548* is discussed as a low penetrance risk allele for breast cancer [47]. Of note, we found no genetic alteration in molecular mechanisms such as TLR, IFN-α/β, or interleukin signaling previously associated with myocarditis. Low penetrant immune phenotypes might induce clinical problems only after special triggers such as DCM with the phenotype of myocarditis. However, the limited understanding of monoallelic deactivation for most immune disease genes hinders further genetic interpretation. This limitation will be overcome by future functional and clinical characterization of these genes and genetic variants.

Considering the immune-related genes, this study found genetic variants in genes such as CCDC40, DNAH9, DNAH11, PIH1D3, and SPAG1 directly or indirectly associated with ciliary transport. The primary cilium is a specialized, non-motile cellular extrusion implicated in sensing and cellular signaling required for many developmental processes and cellular functions [48]. More importantly, DNAH9, DNAH11, PIH1D3, and SPAG1 were classified as primary ciliary dyskinesia (PCD) disease genes typically with AR inheritance; PIH1D3 follows X-linked recessive (XLR) inheritance [49]. Most frequently, PCD is linked to left–right axis abnormalities, defects in cardiac development, conductive hearing problems, subfertility, and respiratory problems associated with respiratory infections; typically, with biallelic gene deactivation. Moderate, subclinical phenotypes after the mutation of CCDC40, DNAH9, DNAH11, PIH1D3, and SPAG1 have not been described. In immune cells, the immunological synapse serves as a molecular interface between the antigen-presenting cell and the interacting, activated lymphocyte [50]. From a molecular perspective, the immunological synapse is a specialized cilium structure sharing, for instance, similarities in centrosomal positioning at the plasma membrane, actin organization, and molecules facilitating intraciliary trafficking [50]. No association of CCDC40, DNAH9, DNAH11, PIH1D3, and SPAG1 gene function with the immunological synapse has been identified so far. Moreover, all five genes are highly expressed in the respiratory system, primarily suggesting a role in respiratory epithelial function [47,51–53]. Within the heart, the ciliary function is discussed in endothelial regulation influencing hypertension and atherosclero-
sis [54]. Further, an accumulation of ciliated fibroblasts after myocardial injury could be detected indicating a potential role in the development of cardiac fibrosis [55]. Together, this raises the hypothesis that altered cilium function directly or indirectly predisposes for myocardial and/or inflammation in the context of CMP.

Study Limitations

The interpretation of immune disease gene variants is limited due to the incomplete understanding of the clinical impact after monoallelic deactivation; a significant proportion of immune diseases are inherited recessively. Our genetic analysis approach assessed small genetic variation within or close to coding regions but did not test for other genomic alterations such as deep intronic or copy number variants. Currently, most of the exonic missense variants in immune disease genes are not interpretable due to a lack of knowledge. The study has an explorative character and requires complementation with further families and genetic burden analysis to solicit or reject the findings from the current analysis.

5. Conclusions

This study supports the idea that pediatric myocarditis with the DCM phenotype may be caused by the mutation of known CMP genes. Piloting the idea that additional immune-related genetic defects promote inflammation revealed truncation and (L)P variants in immune disease genes. These variants were present in the monoallelic, heterozygous state. Expanded analysis of individuals with pediatric myocarditis and the DCM phenotype will identify immune-related genetic factors predisposing one to myocardial inflammation.

Author Contributions: Conceptualization, F.S., S.K. and J.K.; methodology, F.S., J.D., S.T., H.M., S.K. and J.K.; software, M.H. and D.B.; formal analysis, F.S., K.K. and J.K.; investigation, F.S., K.K., F.B., K.T.L., S.S. and S.K.; resources, M.H., D.B., K.T.L., A.G., H.M. and T.P.; data curation, F.S., K.K., S.T., K.T.L., H.M., S.S., S.K. and J.K.; writing—original draft preparation, F.S. and J.K.; writing—review and editing, K.K., T.P., F.B., K.T.L., H.M., S.S. and S.K.; project administration, F.S. and J.K.; funding acquisition, F.S., F.B., S.S. and S.K. All authors have read and agreed to the published version of the manuscript.

Funding: Supported by the DZHK (German Centre for Cardiovascular Research) with grants 81X2100230, 81Z0100301, and 81Z3100333. Supported by kinderherzen-Fördergemeinschaft Deutsche Kinderherzzentren e.V. (Bonn, Germany). Parts of the study were funded by a research grant from the Berliner Sparkassen Stiftung Medizin (2019-043). Parts of the study were supported by the Erich and Hanna Klessmann foundation, Gütersloh, Germany (HM). Parts of the study were funded by a research grant from the “Förderverein des Herz- und Diabeteszentrums Nordrhein-Westfalen e.V.” (SS). The National Register for Congenital Heart Defects Germany has provided infrastructure for this project and is funded by the German Federal Ministry of Education and Research (BMBF), grant no: 01KKX2140.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, ap-proved by the institutional ethics committee (Charité-Universitätsmedizin Berlin, ID EA2/083/13, EA2/131/10, EA2/074/13; University Clinic of Ruhr University Bochum, Bad Oeynhausen for MYKKE 65/2013 and Biobank 21/2013).

Informed Consent Statement: All parents/guardians of patients <18 years gave written informed consent.

Data Availability Statement: Not applicable.

Acknowledgments: We thank the patients and their families for participating in this study. We thank the National Register for Congenital Heart Defects, Germany for supporting the infrastructure of MYKKE (Multicenter registry of pediatric patients with myocarditis) and the Central Biobank Charité/BIH (https://biobank.charite.de/en, accessed on 1 April 2021) for sample preparation.

Conflicts of Interest: The authors declare no conflict of interest.
45. Rosenbaum, A.N.; Agre, K.E.; Pereira, N.L. Genetics of dilated cardiomyopathy: Practical implications for heart failure management. *Nat. Rev. Cardiol.* 2019, 17, 286–297. [CrossRef]
46. Van Linthout, S.; Tschope, C. The Quest for Antiinflammatory and Immunomodulatory Strategies in Heart Failure. *Clin. Pharmacol.* 2019, 106, 1198–1208. [CrossRef]
47. Schwabe, G.C.; Hoffmann, K.; Loges, N.T.; Birker, D.; Rossier, C.; de Santi, M.M.; Olbrich, H.; Fliegauf, M.; Fainly, M.; Liebers, U.; et al. Primary ciliary dyskinesia associated with normal axoneme ultrastructure is caused by DNAH11 mutations. *Hum. Mutat.* 2008, 29, 289–298. [CrossRef]
48. Chaudhry, B.; Henderson, D.J. Cilia, mitochondria, and cardiac development. *J. Clin. Investig.* 2019, 129, 2666–2668. [CrossRef]
49. Wheway, G.; Mitchison, H.M.; Genomics England Research Consortium. Opportunities and Challenges for Molecular Understanding of Ciliopathies—The 100,000 Genomes Project. *Front. Genet.* 2019, 10, 127. [CrossRef]
50. Douanne, T.; Stinchcombe, J.C.; Griffiths, G.M. Teasing out function from morphology: Similarities between primary cilia and immune synapses. *J. Cell Biol.* 2021, 220, e202102089. [CrossRef]
51. Fassad, M.R.; Shoemark, A.; Legendre, M.; Hirsz, R.A.; Koll, F.; le Borgne, P.; Louis, B.; Daudvohra, F.; Patel, M.P.; Thomas, L.; et al. Mutations in Outer Dynein Arm Heavy Chain DNAH9 Cause Motile Cilia Defects and Situs Inversus. *Am. J. Hum. Genet.* 2018, 103, 984–994. [CrossRef] [PubMed]
52. Olcese, C.; Patel, M.P.; Shoemark, A.; Kiviluoto, S.; Legendre, M.; Williams, H.J.; Vaughan, C.K.; Hayward, J.; Goldenberg, A.; Emes, R.D.; et al. X-linked primary ciliary dyskinesia due to mutations in the cytoplasmic axonemal dynein assembly factor PHH1D3. *Nat. Commun.* 2017, 8, 14279. [CrossRef] [PubMed]
53. Patir, A.; Fraser, A.M.; Barnett, M.W.; McTeir, L.; Rainger, J.; Davey, M.G.; Freeman, T.C. The transcriptional signature associated with human motile cilia. *Sci. Rep.* 2020, 10, 10814. [CrossRef] [PubMed]
54. Pala, R.; Jamal, M.; Alshammari, Q.; Nauli, S.M. The Roles of Primary Cilia in Cardiovascular Diseases. *Cells* 2018, 7, 233. [CrossRef]
55. Villalobos, E.; Criollo, A.; Schiattarella, G.G.; Altamirano, F.; French, K.M.; May, H.I.; Jiang, N.; Nguyen, N.U.N.; Romero, D.; Roa, J.C.; et al. Fibroblast Primary Cilia Are Required for Cardiac Fibrosis. *Circulation* 2019, 139, 2342–2357. [CrossRef] [PubMed]